Riskpilot← Back to searchSign inGet full accessbiomee ApS
APSActiveCVR 29829586Agern Alle 24-26Research and experimental development on natural sciences and engineering · NACE 7210Est. 2006— employees
Revenue 2024
DKK 4,4M
-41% vs 2023
EBITDA margin
100.0%
-41% vs 2023
Equity ratio
92.7%
Financial strength
Net profit 2024
DKK 5,5M
-29% vs 2023
| Revenue | DKK 4,4M | -41% |
| EBITDA | DKK 4,4M | -41% |
| Net profit | DKK 5,5M | -29% |
| Total assets | DKK 18,6M | +49% |
| Equity | DKK 17,2M | +48% |
| Employees | — | — |
Legal name
biomee ApS
CVR number
29829586
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
18. december 2006
Share capital
DKK 1.000.000
Employees
—
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af direktøren.
Company purpose
Selskabets formål er at drive virksomhed ved forskning, udvikling og handel indenfor biotek og anden hermed beslægtet virksomhed.
Address
Agern Alle 24-26
Phone
+4520181111
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -10.988 | -15.515 | -18.320 | -32.171 | -33.025 | -7.813 | -386 | -273 | -461 | 8.631 | 3.552 | 7.519 | 4.444 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -10.988 | -15.515 | -18.320 | -32.171 | -33.025 | -7.813 | -386 | -273 | -461 | 8.631 | 3.552 | 7.519 | 4.444 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -10.988 | -15.515 | -18.320 | -32.171 | -33.025 | -7.813 | -386 | -273 | -461 | 8.631 | 3.552 | 7.519 | 4.444 |
| Net financials | -1.791 | -2.683 | -3.564 | -5.116 | -2.169 | -2.398 | -2.074 | -2.147 | -2.248 | -844 | 50 | 348 | 1.103 |
| Profit before tax | -12.779 | -18.198 | -21.884 | -37.287 | -35.194 | -10.211 | -2.460 | -2.420 | -2.709 | 7.786 | 3.602 | 7.867 | 5.547 |
| Tax | -1.011 | 398 | -4.653 | -4.297 | 3.513 | -5.980 | -87 | -67 | 67 | -0 | -0 | -0 | -0 |
| Net profit | -11.768 | -18.595 | -17.231 | -32.989 | -38.707 | -4.231 | -2.373 | -2.353 | -2.776 | 7.786 | 3.602 | 7.867 | 5.547 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1.853 | 422 | 5.038 | 7.198 | 3.151 | 4.625 | 3.411 | 232 | 199 | 1.222 | 4.763 | 12.434 | 18.574 |
| Equity | -42.846 | -61.442 | -78.673 | -7.134 | -45.841 | -50.072 | -52.445 | -54.798 | -57.574 | 208 | 3.810 | 11.677 | 17.224 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 44.700 | 61.864 | 83.711 | 14.333 | 48.992 | 54.697 | 55.855 | 55.029 | 57.773 | 1.014 | 953 | 757 | 1.350 |
| Total debt | 44.700 | 61.864 | 83.711 | 14.333 | 48.992 | 54.697 | 55.855 | 55.029 | 57.773 | 1.014 | 953 | 757 | 1.350 |
EBITDA margin
100.0%
This company
15.8%
Market median
+533% vs market
20122024
Equity ratio
92.7%
This company
38.2%
Market median
+143% vs market
20122024
Return on equity
32.2%
This company
18.4%
Market median
+75% vs market
20122024
Net profit margin
124.8%
This company
8.1%
Market median
+1441% vs market
20122024
Asset turnover
0.24×
This company
1.12×
Market median
-79% vs market
20122024
Debt / equity
0.08×
This company
0.62×
Market median
+87% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
TA Management | Management | 2025 | — | — |
JJ Management | Management | 2006 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
MC2 Therapeutics A/S | Company | 100.0% | 100.0% | 2017 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Elsmark ApS
biomee ApS Board members of biomee ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Trine Ahlgreen | Management | 0 companies |
| Jesper Jørn Lange | Management | 0 companies |